A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 315 participants.

Also called NCT03842267

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 315 participants (enrolled count) (from the registry)
Sponsor
LG Chem (from the registry)
Registry
  • NCT NCT03842267
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03842267. Randomized; double masking; primary purpose treatment. Start 2019-05-13 (actual); primary completion 2021-05-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Gemigliptin 50mg
Intervention (Drug)
Gemigliptin Placebo
Lead sponsor
LG Chem (class: industry)

Record details

Record id
cardio:ct-nct03842267
Content hash
bff0bbf0e2dc61a10f3d2b6d5538ad9b8ae65e0fb797e91c3626735772d54cd5